Determinants of HIV progression and assessment of the optimal time to initiate highly active antiretroviral therapy: PISCIS Cohort (Spain).
Jaén A, Esteve A, Miró JM, Tural C, Montoliu A, Ferrer E, Riera M, Segura F, Force L, Sued O, Vilaró J, Garcia I, Masabeu A, Altès J, Coltet B, Podzamczer D, Murillas J, Navarro G, Gatell JM, Casabona J; PISCIS Study Group.
Jaén A, et al. Among authors: sued o.
J Acquir Immune Defic Syndr. 2008 Feb 1;47(2):212-20. doi: 10.1097/qai.0b013e31815ee282.
J Acquir Immune Defic Syndr. 2008.
PMID: 18297762